Micro-Leads Medical, Inc., a Somerville, Mass.-based clinical neurostimulation startup developing a high-resolution spinal cord stimulation therapy for treating chronic focal pain without opioids, was awarded $10 million in therapy development funding.
With the funding, the company will further develop its HD64TM implantable therapy system and launch a clinical study in patients led by Julie Pilitsis, M.D., Ph.D., chair of the Department of Neuroscience and Experimental Therapeutics and professor of Neurosurgery at Albany Medical College.
The funding came from the National Institutes of Health initiative Helping to End Addiction Long-Term (HEAL) and private investors. It will span multiple years pending completion of milestones.
Led by Bryan McLaughlin, Ph.D., CEO, Micro-Leads Medical is a medical technology company dedicated to developing innovative therapies that address the neuromodulation and bioelectronic medicine market. Its high-resolution spinal cord stimulation therapy to treat chronic back and focal pains without opioids.
HD64TM therapy uses conformal surgical and percutaneous lead technology to deliver maximum dosing of low- and high-frequency stimulation without side effects such as discomfort or repeat surgeries from loss of therapy.
Prior to this award, the company has received extensive development funding from Galvani Bioelectronics, the National Institutes of Health, Defense Advanced Research Projects Agency, the National Science Foundation, and the Massachusetts Life Science Center to develop the underlying closed-loop neuromodulation device technology.